Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Subjects aged 18 to 75 years with a diagnosis of CD for at least 3 months;~2. Moderately to severely active CD as defined by: a CDAI score of 220 450, and an SES-CD scored ≥ 6 ( ≥ 4 for isolated ileitis) (centrally read);~Key exclusion criteria:~1. Ulcerative colitis;~2. Known current bacterial or parasitic pathogenic enteric infection; live virus vaccination within 12 weeks of screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BT-11 880 mg (Type: EXPERIMENTAL): Oral once daily tablet
- Placebo (Type: PLACEBO_COMPARATOR): Oral once daily tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).